Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)

@article{Bialer2004ProgressRO,
  title={Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)},
  author={Meir Bialer and Svein I Johannessen and Harvey J. Kupferberg and Ren{\'e} H Levy and Emilio Perucca and Torbj{\"o}rn Tomson},
  journal={Epilepsy Research},
  year={2004},
  volume={61},
  pages={1-48}
}
The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the 9th to 13th May 2004. Basic scientists, clinical pharmacologists and neurologists from 24 countries attended the conference,whose main themes included advances in pathophysiology of drug resistance, new AEDs in pediatric epilepsy syndromes, modes of AED action and spectrum of adverse effects and a re-appraisal of comparative responses to AED combinations. Consistent… 
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
TLDR
This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate, fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369.
Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)
TLDR
The Tenth EILat Conference on New Antiepileptic Drugs (AEDs)-EILAT X, took place in Eilat, Israel from the 25th to 29th of April 2010, whose main themes included learning from the past and Detecting assessing and preventing adverse effects of AEDs.
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
TLDR
Preclinical and clinical pharmacology of AEDs that are currently in development that include adenosine-releasing silk, allopregnanolone, AMP-X-0079, and twelve novel potential epilepsy treatments are presented for the first time.
New antiepileptic drugs that are second generation to existing antiepileptic drugs
  • M. Bialer
  • Medicine
    Expert opinion on investigational drugs
  • 2006
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their favourable pharmacokinetics, improved tolerability and lower potential
Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development
TLDR
There continues to be a steady flow of potential antiepileptic drugs progressing to clinical development, and many of these compounds show innovative mechanisms of action, and some have already been tested in placebo‐controlled randomized controlled trials, with promising efficacy and safety results.
Pharmacological Management of Epilepsy
TLDR
This review provides updated data on proposed mechanisms of action, efficacy and tolerability on these new AEDs, and to discuss the rationale for their development and possible advantages compared with existing treatment, based on recent publications and MEDLINE searches.
The Pharmacokinetics and Interactions of New Antiepileptic Drugs: An Overview
  • M. Bialer
  • Medicine
    Therapeutic drug monitoring
  • 2005
TLDR
New AEDs have better PK profies and are less involved in drug interactions than the 4 established AEDS: phenobarbital, phenytoin, carbamazepine, and valproic acid, however, in spite of the large therapeutic arsenal of old and new Aeds, about 30% of epileptic patients are still not seizure-free, and thus, there is a substantial need to develop new A EDs.
Novel Medications for Epilepsy
TLDR
The ability of these agents to cause pharmacokinetic drug interactions appears to be relatively modest, although eslicarbazepine can cause a significant decrease in the blood levels of ethinylestradiol, levonorgestrel and simvastatin.
Diverse mechanisms of antiepileptic drugs in the development pipeline
TLDR
There is a remarkable array of new chemical entities in the current antiepileptic drug (AED) development pipeline, and some pipeline compounds are believed to act through conventional targets, whereas others are structurally novel and may act by novel mechanisms.
A Clinical Overview of the New Antiepileptic Drugs
TLDR
All the new anti-epileptic drugs are also effective as add-on therapy for partial seizures without or with secondary generalization.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 275 REFERENCES
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
TLDR
Information presented on drugs in preclinical and clinical development, including carabersat, CGX-1007 (Conantokin-G), pregabalin, retigabine (D-23129), safinamide, SPD421 (DP-VPA), SPM 927, talampanel and valrocemide are summarized.
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
TLDR
This article summarizes the information presented on drugs in preclinical and clinical development, including AWD 131-138, DP-valproate, harkoseride, LY300164, NPS 1776, NW 1015, pregabalin, remacemide, retigabine, rufinamide and valrocemide.
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
TLDR
A review of drugs in development and recently marketed AEDs and of a new antiepileptic device, the neurocybernetic prosthesis (NCP), has become available.
Future Prospects for the Drug Treatment of Epilepsy
TLDR
This review looks at possible avenues of development in the drug treatment of epilepsy, and a summary of the most promising AEDs currently in development is provided.
Drugs Under Clinical Trial
TLDR
Over the last decade, the introduction of novel antiepileptic drugs brought new hope to the multitude of patients whose seizures are not completely controlled by established anticonvulsants but none of the new agents is ideal in terms of its pharmacokinetic properties, interaction potential, spectrum of activity and side effect profile.
Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials
PURPOSE To assess the influence of commonly used antiepileptic drugs (AEDs) on levetiracetam pharmacokinetics at steady state. METHODS Plasma levetiracetam concentrations at steady state were
Levetiracetam, a New Antiepileptic Agent: Lack of In Vitro and In Vivo Pharmacokinetic Interaction with Valproic Acid
TLDR
The novel antiepileptic drug (AED) levetiracetam (LEV; Keppra) has a wide therapeutic index and pharmacokinetic characteristics predicting limited drug‐interaction potential, and thus coadministration with valproic acid (VPA) is likely.
Pregabalin (Pfizer).
  • I. Selak
  • Medicine
    Current opinion in investigational drugs
  • 2001
Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for the potential treatment of several central nervous system (CNS) disorders including epilepsy, neuropathic
Pharmacokinetic Interactions of Topiramate
TLDR
A critical review of the pharmacokinetic interactions of topiramate with old and new AEDs, an oral contraceptive, and the CNS-active drugs lithium, haloperidol, amitriptyline, risperidone, sumatriptan, propranolol and dihydroergotamine is provided.
Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig
TLDR
The data show that oxcarbazepine and other AEDs are effective anti‐hyperalgesic or anti‐allodynic agents in an animal model of neuropathic pain, and provide further support for their use in the treatment of neuropathy pain in the clinic.
...
1
2
3
4
5
...